NEW YORK, Dec. 13, 2012 /PRNewswire/ -- Reportlinker.com
announces that a new market research report is available in its
catalogue:
The Outlook for Pharmaceuticals in South East Asia
http://www.reportlinker.com/p0203106/The-Outlook-for-Pharmaceuticals-in-South-East-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
The eight pharmaceutical markets of South East Asia are developing at markedly
different speeds and are characterised by both contrasting and
similar macroenvironments. These markets are projected to have a
total pharmaceutical market value of US$69.1
billion at retail prices in 2016.
Established…South Korea is the largest market in this region and
the fourth largest in the Asia
Pacific region. Other advanced markets such as Taiwan and Singapore are both relatively small, with
growth limited by the size of these island nations. These three
countries have a high percentage of population over 65, a growing
incidence of lifestyle diseases and large health expenditures,
which present many opportunities for pharmaceutical companies.
However, their governments are increasingly employing protectionist
measures that deter foreign companies. The biologic sectors in
these markets are witnessing rapid growth due to advanced
technology capabilities, extensive R&D operations and strong
government support.
Emergent…
Indonesia, Thailand and the
Philippines are fairly large emergent pharmaceutical
markets, with large populations and steadily growing economies.
Despite concerns over counterfeiting and low efficacy of generic
products, IPR protection and manufacturing standards are improving
thanks to effective national regulations, foreign investment and
joint-ventures with multinational companies. Malaysia and Vietnam are small pharmaceutical markets,
typified by rapid economic growth, increasing foreign investment
and support from national government. These five markets have
significant OTC sectors and rapidly expanding generic sectors, and
present previously untapped populations for potential foreign
pharmaceutical companies.
Complete quarterly-updated analysis to keep you informedNow you
can easily evaluate these markets with The Outlook for
Pharmaceuticals in South East
Asia. Each report provides individual and highly-detailed
analysis of the market, looking at the key regulatory, political,
economic and corporate developments in the wider context of market
structure, service and access. The reports are available
individually, or as a discounted collection, and prices include
eight completely updated reports sent quarterly, together with a
comprehensive statistical appendix. There are over 60 markets
covered in the worldwide series. Focus on Biotechnolog - A
research-friendly environment...These markets are keen to attract
high value investment and have identified biotechnology and
biopharmaceutical research as key areas. Their governments strongly
advocate the growth of biotechnology.
Malaysia
The government has indentified biotechnology as one the core
technologies to accelerate the transformation of the country into a
knowledge-based economy by the year 2020. As a result of this
initiative, a number of new biopharmaceutical research companies
have emerged.
SingaporeThe biologic sector is growing, with several large
multinational companies investing a total of US$2.0 billion to set up biologic facilities. The
government is increasing its investment in biomedical sciences
research over the period 2011 to 2015.
South Korea
The biologic sector is witnessing rapid growth and many domestic
companies have expanded their operations in 2011. Several
significant competitive strategies have been completed in 2011.
TaiwanThe government has been investing heavily in biotechnology
research capability and this has helped facilitate the growth of
the biologic sector. The plan is to double the annual output of the
sector over the period 2009 to 2013. INDONESIADue to the sheer size
of the population, Indonesia
cannot simply be dismissed. The Indonesian pharmaceutical market is
projected to grow at a high single-digit CAGR in US dollar terms
during the forecast period, and it will be the sixth largest
pharmaceutical market in the Asia
Pacific region by 2016. However, despite the country
possessing huge manufacturing capabilities, the complete lack of
R&D in domestic companies could affect the market, especially
if IPR regulations were tightened. Although multinationals will be
unhappy at the legislation requiring all drugs in the Indonesian
market to have been manufactured in Indonesia, it could potentially reduce costs
in the long term for both the manufacturer and the consumer.
MALAYSIA
The Philippines has some of the
highest drug prices in the world. Changes brought about by the
controversial Cheaper Medicine Act have impacted the Philippines pharmaceutical market in a
number of areas, including IP laws, competition and drug price
control mechanisms. Since the Act's implementation, a considerable
number of drugs have seen price reductions by up to a half. The
immediate term will be the most volatile, as the government battles
with the international pharmaceutical industry for ground in the
market, which up until recently experienced a free-market policy
with no price regulations in place.
SOUTH KOREAThe implementation of the EU-Korea Free Trade
Agreement (FTA) will provide EU companies with better access to the
South Korean pharmaceutical market by paving the way for
elimination of tariffs on EU pharmaceutical exports to the country.
The volume and value of EU pharmaceutical exports are expected to
increase with the implementation of EU-Korea FTA, posing a
potential threat to US pharmaceutical exporters. The EU-Korea FTA
also stipulates that South Korean authorities will be required to
align their practices with international standards through an
improved regulatory environment. In particular, the EU-Korea FTA
will aim to ensure the strengthening of transparency in drug
pricing decisions.
VIETNAM
The Drug Administration of Vietnam (DAV) has warned that drug prices
could rise slightly in 2011 due to volatile raw material prices and
the VND-US$ exchange rate. The Vietnam Pharmaceutical Companies
Association (VNPCA) has forecasted higher sales prices for both
imported and Vietnamese drugs in 2011, due to higher input costs
and rising world prices. To review the local pharmaceutical market
and prevent large drug price increases, the DAV has announced
several measures that include; stepping-up the inspection of drug
price quotations by pharmaceutical companies, supervising the
enforcement of state regulations on drug price management and
exercising sanctions on violators.
To order this report:Drug_and_Medication Industry: The
Outlook for Pharmaceuticals in South East Asia
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker